ASX:VIT

VITURA

ASX ANNOUNCEMENT

Update on Chief Financial Officer Transition and Appointment of Interim CFO

5 JUNE 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) ("Vitura" or "the Company") provides the following update in relation to the Chief Financial Officer (CFO) transition announced on 3 June 2026.

Appointment of Interim CFO

Vitura is pleased to advise that Mr Tom Howitt has been appointed Interim Chief Financial Officer, effective immediately.

Mr Howitt previously served as Vitura's CFO for seven years and brings a deep understanding of the Company's operations, financial profile and strategic priorities. He has a strong professional commitment to Vitura's potential and is well placed to work closely with Chief Executive Officer, Mr Justin James, and the finance team to ensure continuity and strong stewardship of the business over the coming months.

Context for Andrew Cook's Resignation

As announced on 3 June 2026, Mr Andrew Cook resigned from the role of CFO within the probationary period of his tenure. Subsequent to that announcement, and with Mr Cook's consent, the Company can confirm that his decision followed an unsolicited approach for a senior role external to Vitura that represented a unique professional opportunity aligned to his long-term career aspirations.

The Board acknowledges that the timing of a CFO change is not ideal; however, it respects Mr Cook's decision and thanks him for his contribution during his time with the Company.

CFO Recruitment and Transformation Agenda

The change in CFO also creates an opportunity for Mr James, who commenced as CEO recently, to lead the recruitment process for a permanent CFO who will be a close partner in delivering Vitura's transformation strategy. Vitura is seeking an experienced finance leader with a proven track record in:

- Driving financial and operational performance improvement through business transformation in comparable growth and healthcare or technology-enabled businesses.
- Leading high-calibre finance functions with strong business partnering across commercial, operations and technology teams.
- Managing elevated investor relations and capital management programs, including clear communication of strategy, performance and value creation to shareholders and other stakeholders.
- Designing and implementing data-driven financial insights and business solutions that support scalable, resilient growth.

An executive search process for a permanent CFO is already underway, and the Company will update the market in accordance with its continuous disclosure obligations.

ENDS

Authorised by – The Board of Vitura Health Limited.

Contact

Vitura Health Limited

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au
  Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
  Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au
  Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integrationsoftware owned and opearated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

  Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

  While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
  The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

- www.cortexa.com.au
  The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

- www.candor.com.au
  The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

- www.releaf.com.au
  The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

- www.cdaclinics.com.au
  The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

- www.cannadoc.com.au
  The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.